Trial Profile

A Study to Evaluate the Efficacy and Safety of Romiplostim in Patients with Primary Immune Thrombocytopenia

Status: Recruiting

Phase of Trial: Phase IV

Latest Information Update: 08 Aug 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Romiplostim (Primary)
Indications Idiopathic thrombocytopenic purpura
Focus Adverse reactions; Therapeutic Use
Acronyms Plateau

Most Recent Events

17 Jun 2021 Results of post hoc analysis assessing the effectiveness and safety of romiplostim in adults with primary ITP, according to ITP phase, in routine clinical practice in Germany presented at the 26th Congress of the European Haematology Association
25 Jun 2017 Results (n=59) presented at the 22nd Congress of the European Haematology Association
09 Dec 2015 New trial record

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com